Foghorn Therapeutics (FHTX) Operating Expenses (2019 - 2026)

Foghorn Therapeutics' Operating Expenses history runs 8 years deep, the most recent figure standing at $24.8 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 13.94% year-over-year to $24.8 million; the TTM figure through Mar 2026 stood at $113.3 million (down 6.31% YoY), while the FY2025 annual figure was $117.3 million, down 6.38% from the prior year.
• Operating Expenses for Q1 2026 stood at $24.8 million, down from $33.1 million in the prior quarter.
• The five-year high for Operating Expenses was $38.6 million in Q1 2023, with the low at $24.8 million in Q1 2026.
• The 5-year median for Operating Expenses is $33.1 million (2025), against an average of $32.1 million.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses surged 43.07% in 2022, then declined 15.81% in 2025.
• Foghorn Therapeutics' Operating Expenses stood at $36.1 million in 2022, then retreated by 13.43% to $31.2 million in 2023, then slipped by 13.98% to $26.9 million in 2024, then grew by 23.32% to $33.1 million in 2025, then retreated by 25.01% to $24.8 million in 2026.
• Business Quant data shows FHTX's Operating Expenses at $24.8 million in Q1 2026, $33.1 million in Q4 2025, and $26.7 million in Q3 2025.